ImmuPharma PLC
  • Announcements
  • About Us
    • About Us
    • Our Team
    • Board of Directors
  • Our Science
    • Our Science
    • ImmuPharma Biotech
    • Key Clinical Investigators
  • Pipeline
    • Pipeline
    • Autoimmunity & Inflammation
    • Anti-Infectives
  • Partnerships & Collaborations
  • Investors
    • Investors
    • AIM Rule 26 Information
    • Regulatory News
    • Corporate Governance
    • Board of Directors
    • Annual Reports
    • Analyst Research
    • Interviews
    • Professional advisers
    • Email Alerts
  • Contact
Archives
  • 2025
  • 2024
  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013
  • 2012
  • 2011
March 21, 2017

Notification of Major Interest by Legal & General

Read More
March 10, 2017

Successful £4.1 Million Fund Raise Following the Close of the Accelerated Bookbuild

Read More
March 10, 2017

Accelerated Bookbuild for the Issue of Equity

Read More
January 25, 2017

Update on Lupuzor™ Pivotal Phase III Study – Full Analysis of Patient Recruitment

Read More
January 24, 2017

Change of Adviser

Read More
  • 1
  • 2
  • Keep up-to-date with email alerts

  • @immupharma

Aim Rule 26 Contact informationDisclaimerPrivacy PolicySite map

© ImmuPharma PLC 2005-2022 | All rights reserved